Multivariable Fine and Gray model of risk of developing TA-TMA
| . | HR . | 95% CI . | P . | |
|---|---|---|---|---|
| ATG use | 0.47 | 0.30 | 0.75 | .001 |
| GVHD status* | ||||
| Not yet developed | 0.35 | 0.14 | 0.88 | .025 |
| Steroid-responsive | 1.00 | |||
| Steroid-refractory | 3.09 | 1.68 | 5.67 | <.001 |
| Steroid-dependent | 2.42 | 1.17 | 4.98 | .017 |
| Viral infection other than CMV | 2.15 | 1.37 | 3.38 | .001 |
| Fungal infection | 5.87 | 1.35 | 25.55 | .018 |
| . | HR . | 95% CI . | P . | |
|---|---|---|---|---|
| ATG use | 0.47 | 0.30 | 0.75 | .001 |
| GVHD status* | ||||
| Not yet developed | 0.35 | 0.14 | 0.88 | .025 |
| Steroid-responsive | 1.00 | |||
| Steroid-refractory | 3.09 | 1.68 | 5.67 | <.001 |
| Steroid-dependent | 2.42 | 1.17 | 4.98 | .017 |
| Viral infection other than CMV | 2.15 | 1.37 | 3.38 | .001 |
| Fungal infection | 5.87 | 1.35 | 25.55 | .018 |
GVHD status was treated as a time-dependent covariate in the model.